Not a healthcare professional? Go to the patient or caregiver website.

DILANTIN® Extended Oral Capsules Drug Interactions (phenytoin)

7 DRUG INTERACTIONS

Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Phenytoin is metabolized by hepatic cytochrome P450 enzymes CYP2C9 and CYP2C19, and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity. Monitoring of phenytoin serum levels is recommended when a drug interaction is suspected.

Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.

7.1 Drugs that Affect Phenytoin Concentrations

Table 2 includes commonly occurring drug interactions that affect phenytoin concentrations. However, this list is not intended to be inclusive or comprehensive. Individual prescribing information from relevant drugs should be consulted.

The addition or withdrawal of these agents in patients on phenytoin therapy may require an adjustment of the phenytoin dose to achieve optimal clinical outcome.

Table 2: Drugs That Affect Phenytoin Concentrations
Interacting Agent Examples
*
Antacids may affect absorption of phenytoin.
The induction potency of St. John's wort may vary widely based on preparation.
Drugs that may increase phenytoin serum levels
  Antiepileptic drugs Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate
  Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole
  Antineoplastic agents Capecitabine, fluorouracil
  Antidepressants Fluoxetine, fluvoxamine, sertraline
  Gastric acid reducing agents H2 antagonists (cimetidine), omeprazole
  Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim
  Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin
Drugs that may decrease phenytoin serum levels
  Antacids* Calcium carbonate, aluminum hydroxide, magnesium hydroxide
  Prevention or Management: Phenytoin and antacids should not be taken at the same time of day
  Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate
  Antiviral agents Fosamprenavir, nelfinavir, ritonavir
  Antiepileptic drugs Carbamazepine, vigabatrin
  Other Chronic alcohol abuse, diazepam, diazoxide, folic acid, reserpine, rifampin, St. John's wort, sucralfate, theophylline
Drugs that may either increase or decrease phenytoin serum levels
  Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid

7.2 Drugs Affected by Phenytoin

Table 3 includes commonly occurring drug interactions affected by phenytoin. However, this list is not intended to be inclusive or comprehensive. Individual drug package inserts should be consulted. The addition or withdrawal of phenytoin during concomitant therapy with these agents may require adjustment of the dose of these agents to achieve optimal clinical outcome.

Table 3: Drugs Affected by Phenytoin
Interacting Agent Examples
*
The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels is unpredictable
Drugs whose efficacy is impaired by phenytoin
  Azoles Fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole
  Antineoplastic agents Irinotecan, paclitaxel, teniposide
  Delavirdine Phenytoin can substantially reduce the concentrations of delavirdine. This can lead to loss of virologic response and possible resistance [see Contraindications (4)].
  Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown.
  Prevention or Management: Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher.
  Warfarin Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin
  Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D
Drugs whose level is decreased by phenytoin
  Antiepileptic drugs* Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine,
  Antilipidemic agents Atorvastatin, fluvastatin, simvastatin
  Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir
Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of fosamprenavir and ritonavir may increase the concentration of amprenavir
  Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil
  Other Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine

7.3 Drug Enteral Feeding/Nutritional Preparations Interaction

Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin serum levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.

7.4 Drug/Laboratory Test Interactions

Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations.

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No